Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
Under the terms, Novavax will refund $123.8 million to the U.K. agency in quarterly payments of $10.3 million over three years, with the final payment due by June 30, 2027.On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine supply contract from July 1, 2022.
11月1日，诺瓦瓦克斯医药公司（纳斯达克：NVAX）与英国卫生安全局（代表英国卫生和社会关怀国务大臣）签署了一份解除与和解协议以及一份修订协议，解决了双方关于2022年7月1日更新的COVID-19疫苗供应合同的争议。
As per the SEC filing, the agreement releases both parties from any claims related to that prior contract.
根据证券交易委员会提交的文件，该协议解除了双方与先前合同相关的任何索赔。
As part of the settlement, Novavax and the U.K. Health Security Agency agreed to end the supply contract and settle disputed upfront payments Novavax previously received.
作为和解的一部分，诺瓦瓦克斯医药公司和英国卫生安全局同意终止供应合同并解决之前诺瓦瓦克斯已收到的有争议的预付款。
Under the terms, Novavax will refund $123.8 million to the U.K. agency in quarterly payments of $10.3 million over three years, with the final payment due by June 30, 2027.
根据协议，诺瓦瓦克斯将在未来三年内以每季度1030万美元的金额向英国机构退款12380万美元，最终付款截至2027年6月30日。
This amount includes $11.3 million in interest, which can be avoided if Novavax pays ahead of schedule. According to the amendment, the first quarterly payment is due on November 30, 2024.
此金额包括1130万美元的利息，如果诺瓦瓦克斯提前支付，可以避免利息。根据修订协议，第一笔季度付款截至2024年11月30日。
The two parties initially entered into a COVID-19 vaccine supply deal in 2020, and the United Kingdom government agreed to purchase 60 million doses of its COVID-19 vaccine.
双方最初于2020年达成COVID-19疫苗供应交易，并英国政府同意购买诺瓦瓦克斯疫苗6000万剂。
The company's protein-based adjuvanted shot NVX-CoV2373 was renamed Nuvaxovid after being authorized by the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) in 2022.
该公司基于蛋白质的佐剂NVX-CoV2373在2022年被英国药品和保健品管局（MHRA）授权后更名为Nuvaxovid。
Recently, the FDA has placed a clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
最近，FDA对诺瓦瓦克斯的COVID-19-流感联合（CIC）和独立流感疫苗候选药物的新药调查申请（IND）提出了临床暂停。
The clinical hold is due to a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a single CIC Phase 2 trial participant outside the U.S. who received the vaccine in January 2023.
临床暂停是由于2023年1月在美国之外一名CIC第2阶段试验参与者出现严重不良事件（SAE）-机能神经病。
Earlier in October, the European Commission approved Novavax's updated 2024-2025 Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older to prevent COVID-19 in the European Union.
今年十月初，欧洲委员会批准了诺瓦瓦克斯医药经更新的2024-2025年 Nuvaxovid 新冠病毒疫苗（重组、佐剂化）(NVX-CoV2705)，用于欧盟境内12岁及以上人群注射雾化剂，以预防新冠病毒。
Price Action: NVAX stock is down 4.61% at $9.05 at last check Wednesday.
股价走势：纳瓦克斯医药股票在上周三最后一检查时下跌4.61%，报9.05美元。
- Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
- 结直肠癌诊断专注的精密科学股票因年度业绩指引疲弱而暴跌，分析师认为存在引人注目的长期入市点。
Photo via Shutterstock
图片来自shutterstock
